Campaigns promoting organ donation in populations affected by drugs have contributed to increase
Blood conservation via intraoperative autologous donation (IAD) is safe and effective in reducing transfusions during cardiac surgery.
PCSK9 inhibitors are a potentially safe lipid-lowering therapy for heart transplant recipients with suboptimal LDL management on statins.
Among patients undergoing cardiac surgery, those with vs without opioid use disorder may have higher rates of complications and encounter greater costs.
Weekend discharge did not increase rates of hospital readmission after cardiac surgery in this study cohort.
Transplant patients with hearts from donors with hepatitis C virus (HCV) infection and obese donors have similar survival rates as patients with other donor hearts.
The FDA has granted Orphan Drug designation for cannabidiol to prevent ischemia and reperfusion injury.
For cardiac surgical patients, the likelihood of readmission has no association with day of discharge.
Acceptance of a heart from an increased-risk donor is associated with a significant survival benefit.
For patients with advanced heart failure who are listed for transplantation, mortality risk is related to adverse events and end-organ dysfunction that vary over time.